Our Science
Novel CA8* Neuromodulation Approach
Addressing the Root Cause of Many Neurological Disorders
Many neurological conditions, from epilepsy, to hearing loss, and chronic pain disorders are caused by hyper-excitable nerve cells (i.e., frequent and prolonged periods of rapid firing activity)
Carbonic Anhydrase-8 (CA8), discovered by our scientists, is a natural peptide that decreases neuronal excitability
Our novel platform technology allows targeted CA8 delivery to nerves in the peripheral and/or central nervous system
Adolore’s toolkit provides the choice from a broad range of promotors specially aimed to selectively express CA8 in a specific neuronal cell population relevant to a particular neurological disorder
Restoring balance to the affected peripheral and/or central neurons addresses the root cause of serious undertreated neurological disorders
The Adolore Platform: Correcting neuronal signal imbalances that are the root cause of many disorders
Hyper-excitable nerves underlying these imbalances are responsible for common debilitating disorders:
- Chronic Pain
- Osteoarthritis Pain
- Others
- Epilepsy
- Fronto-Temporal Disorder
- Hearing loss
- Neuropathy
Adolore aims to revolutionize the care of numerous serious neurological disorders addressing the unmet needs of millions of patients worldwide, with:
Patented targeted therapies – Longer-lasting efficacy – Minimal side effects
CA8* delivered locally by rdHSV activates Kv7 Channels, a Proven and Potent Neurology and Analgesia Drug Target
CA8* Electrophysiology
DRG patch-clamp studies indicate that CA8* delivered with an rdHSV gene-vector induces analgesia via proglongation of Kv7
Kv7 Inhibition Reverses CA8*
DRG patch-clamp studies demonstrate Kv7 specific inhibitor XE991 normalizes delayed hyperpolarization
Validated CA8* MOA: Activation of Kv7 Potassium Channels, A Clinically Proven Approach (e.g. Retigabine, Flupirtine)
